Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04411641




Registration number
NCT04411641
Ethics application status
Date submitted
28/05/2020
Date registered
2/06/2020
Date last updated
19/09/2024

Titles & IDs
Public title
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)
Scientific title
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis
Secondary ID [1] 0 0
U1111-1246-7768
Secondary ID [2] 0 0
EFC16645
Universal Trial Number (UTN)
Trial acronym
HERCULES
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Secondary Progressive Multiple Sclerosis 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Tolebrutinib
Treatment: Drugs - Placebo to match Tolebrutinib

Experimental: SAR442168 - Dose 1 of oral SAR442168 once daily

Placebo comparator: Placebo - Placebo tablet to match SAR442168 once daily


Treatment: Drugs: Tolebrutinib
Pharmaceutical form: Film-coated tablet Route of administration: Oral

Treatment: Drugs: Placebo to match Tolebrutinib
Pharmaceutical form: Film-coated tablet Route of administration: Oral
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
6-month confirmed disability progression (CDP)
Timepoint [1] 0 0
Up to 48 approximately months
Secondary outcome [1] 0 0
3-months change in T25-FW and 9-HPT
Timepoint [1] 0 0
Up to approximately 48 months
Secondary outcome [2] 0 0
3-month CDP
Timepoint [2] 0 0
Up to approximately48 months
Secondary outcome [3] 0 0
New and enlarging T2 hyperintense lesions by MRI
Timepoint [3] 0 0
From Baseline up to approximately 48 months
Secondary outcome [4] 0 0
Time to onset of confirmed disability improvement (CDI)
Timepoint [4] 0 0
From Baseline up to approximately 48 months
Secondary outcome [5] 0 0
Brain volume loss (BVL)
Timepoint [5] 0 0
From 6 Months up to approximately 48 months
Secondary outcome [6] 0 0
Change in cognitive function
Timepoint [6] 0 0
From Baseline up to approximately 48 months
Secondary outcome [7] 0 0
Change in Multiple Sclerosis Quality of Life-54 (MSQoL-54)
Timepoint [7] 0 0
From Baseline up to approximately 48 months
Secondary outcome [8] 0 0
Safety and Tolerability
Timepoint [8] 0 0
From Screening until end of study up to approximately 48 months
Secondary outcome [9] 0 0
Population pharmacokinetics
Timepoint [9] 0 0
Months 6, 9 and 12
Secondary outcome [10] 0 0
Change in plasma neurofilament light chain (NfL)
Timepoint [10] 0 0
From Baseline up to approximately 48 months
Secondary outcome [11] 0 0
Changes in serum Immunoglobulin level
Timepoint [11] 0 0
From Baseline up to approximately 48 months
Secondary outcome [12] 0 0
Change in lymphocyte phenotype subsets
Timepoint [12] 0 0
From Baseline up to approximately 48 months
Secondary outcome [13] 0 0
Change in serum chitinase-3 like protein 1 (Chi3L1)
Timepoint [13] 0 0
From Baseline up to approximately 48 months

Eligibility
Key inclusion criteria
Inclusion criteria :

* 18 to 60 years of age inclusive
* Diagnosis of nonrelapsing secondary progressive multiple sclerosis according to the 2017 McDonald criteria
* Expanded disability status scale (EDSS) between 3.0 to 6.5 points inclusive, at screening
* The participant must have documented evidence of disability progression observed during the 12 months before screening
* Absence of clinical relapses for at least 24 months
* Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
* A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
* Is not a WOCBP OR
* Is a WOCBP and agrees to use an acceptable contraceptive method
Minimum age
18 Years
Maximum age
60 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

* The participant has conditions that would adversely affect study participation such as short life expectancy.
* History of organ transplant.
* Evidence of infection with human immuodeficiency virus (HIV), transplantation, progressive multifocal leukoencephalopathy (PML), active hepatitis B or C, active or latent tuberculosis or other active infections that would adversely affect study participation.
* Persistent chronic or active or recurring system infection, that may adversely affect participation or IMP administration in this study, as judged by the Investigator.
* History of malignancy within 5 years prior to screening.
* History of alcohol or drug abuse within 1 year prior to screening.
* Hospitalized for psychiatric disease within 2 years prior to screening.
* Clinically significant laboratory abnormalities (including evidence of liver injury) or electrocardiogram abnormalities at screening
* Bleeding disorder, known platelet dysfunctionat any time prior to the screening visit
* A platelet count <150 000/µL at the screening visit
* A history of significant bleeding event within 6 months prior to screening, according to the Investigator's judgment such as, but not limited to cerebral or gastrointestinal bleeding.
* Lymphocyte count below the lower limit of normal at screening.
* Recent live (attenuated) vaccine within 2 months before the first treatment visit.
* Recent major surgery (within 4 weeks of screening) or planned major surgery during the study.
* The participant has received medications/treatments for MS within a specified time frame.
* Receiving potent and moderate inducers or inhibitors of cytochrome P450 3A (CYP3A) or potent inhibitors of CYP2C8 hepatic enzymes.
* Receiving anticoagulant or antiplatelet therapy (such as aspirin>81mg/day, clopidogrel, warfarin).
* Contraindications to magnetic resonance imaging (MRI).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
24/09/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
29/08/2024
Sample size
Target
Accrual to date
Final
1131
Recruitment in Australia
Recruitment state(s)
QLD,SA,TAS,VIC
Recruitment hospital [1] 0 0
Investigational Site Number :0360003 - Woolloongabba
Recruitment hospital [2] 0 0
Investigational Site Number :0360002 - Kent Town
Recruitment hospital [3] 0 0
Investigational Site Number :0360004 - Hobart
Recruitment hospital [4] 0 0
Investigational Site Number :0360001 - Fitzroy
Recruitment hospital [5] 0 0
Investigational Site Number :0360006 - Heidelberg West
Recruitment postcode(s) [1] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [2] 0 0
- Kent Town
Recruitment postcode(s) [3] 0 0
7001 - Hobart
Recruitment postcode(s) [4] 0 0
3065 - Fitzroy
Recruitment postcode(s) [5] 0 0
3081 - Heidelberg West
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Minnesota
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
Nevada
Country [15] 0 0
United States of America
State/province [15] 0 0
New Jersey
Country [16] 0 0
United States of America
State/province [16] 0 0
New Mexico
Country [17] 0 0
United States of America
State/province [17] 0 0
New York
Country [18] 0 0
United States of America
State/province [18] 0 0
North Carolina
Country [19] 0 0
United States of America
State/province [19] 0 0
North Dakota
Country [20] 0 0
United States of America
State/province [20] 0 0
Ohio
Country [21] 0 0
United States of America
State/province [21] 0 0
Oregon
Country [22] 0 0
United States of America
State/province [22] 0 0
Pennsylvania
Country [23] 0 0
United States of America
State/province [23] 0 0
South Carolina
Country [24] 0 0
United States of America
State/province [24] 0 0
Tennessee
Country [25] 0 0
United States of America
State/province [25] 0 0
Texas
Country [26] 0 0
United States of America
State/province [26] 0 0
Vermont
Country [27] 0 0
United States of America
State/province [27] 0 0
Wisconsin
Country [28] 0 0
Argentina
State/province [28] 0 0
Buenos Aires
Country [29] 0 0
Argentina
State/province [29] 0 0
Ciudad De Buenos Aires
Country [30] 0 0
Argentina
State/province [30] 0 0
Córdoba
Country [31] 0 0
Argentina
State/province [31] 0 0
San Miguel de Tucuman
Country [32] 0 0
Austria
State/province [32] 0 0
Innsbruck
Country [33] 0 0
Austria
State/province [33] 0 0
Linz
Country [34] 0 0
Austria
State/province [34] 0 0
Wien
Country [35] 0 0
Belarus
State/province [35] 0 0
Vitebsk
Country [36] 0 0
Belgium
State/province [36] 0 0
Bruxelles
Country [37] 0 0
Belgium
State/province [37] 0 0
Edegem
Country [38] 0 0
Belgium
State/province [38] 0 0
Leuven
Country [39] 0 0
Belgium
State/province [39] 0 0
Liège
Country [40] 0 0
Belgium
State/province [40] 0 0
Mons
Country [41] 0 0
Belgium
State/province [41] 0 0
Pelt
Country [42] 0 0
Bulgaria
State/province [42] 0 0
Pleven
Country [43] 0 0
Bulgaria
State/province [43] 0 0
Plovdiv
Country [44] 0 0
Bulgaria
State/province [44] 0 0
Sofia
Country [45] 0 0
Canada
State/province [45] 0 0
British Columbia
Country [46] 0 0
Canada
State/province [46] 0 0
Nova Scotia
Country [47] 0 0
Canada
State/province [47] 0 0
Ontario
Country [48] 0 0
Canada
State/province [48] 0 0
Quebec
Country [49] 0 0
China
State/province [49] 0 0
Beijing
Country [50] 0 0
China
State/province [50] 0 0
Changchun
Country [51] 0 0
China
State/province [51] 0 0
Changsha
Country [52] 0 0
China
State/province [52] 0 0
Chengdu
Country [53] 0 0
China
State/province [53] 0 0
Chongqing
Country [54] 0 0
China
State/province [54] 0 0
Fuzhou
Country [55] 0 0
China
State/province [55] 0 0
Guangzhou
Country [56] 0 0
China
State/province [56] 0 0
Hangzhou
Country [57] 0 0
China
State/province [57] 0 0
Shijiazhuang
Country [58] 0 0
China
State/province [58] 0 0
Taiyuan
Country [59] 0 0
China
State/province [59] 0 0
Xi'an
Country [60] 0 0
Czechia
State/province [60] 0 0
Brno
Country [61] 0 0
Czechia
State/province [61] 0 0
Hradec Kralove
Country [62] 0 0
Czechia
State/province [62] 0 0
Jihlava
Country [63] 0 0
Czechia
State/province [63] 0 0
Ostrava - Poruba
Country [64] 0 0
Czechia
State/province [64] 0 0
Praha 2
Country [65] 0 0
Czechia
State/province [65] 0 0
Teplice
Country [66] 0 0
Denmark
State/province [66] 0 0
Esbjerg
Country [67] 0 0
Denmark
State/province [67] 0 0
Holstebro
Country [68] 0 0
Denmark
State/province [68] 0 0
Odense
Country [69] 0 0
Finland
State/province [69] 0 0
Helsinki
Country [70] 0 0
Finland
State/province [70] 0 0
Tampere
Country [71] 0 0
Finland
State/province [71] 0 0
Turku
Country [72] 0 0
France
State/province [72] 0 0
Bron
Country [73] 0 0
France
State/province [73] 0 0
Clermont Ferrand
Country [74] 0 0
France
State/province [74] 0 0
Gonesse
Country [75] 0 0
France
State/province [75] 0 0
Lille
Country [76] 0 0
France
State/province [76] 0 0
Montpellier
Country [77] 0 0
France
State/province [77] 0 0
Nancy
Country [78] 0 0
France
State/province [78] 0 0
Nantes
Country [79] 0 0
France
State/province [79] 0 0
Nimes
Country [80] 0 0
France
State/province [80] 0 0
Paris
Country [81] 0 0
France
State/province [81] 0 0
Rennes
Country [82] 0 0
France
State/province [82] 0 0
Strasbourg
Country [83] 0 0
France
State/province [83] 0 0
Toulouse
Country [84] 0 0
Germany
State/province [84] 0 0
Bayreuth
Country [85] 0 0
Germany
State/province [85] 0 0
Berlin
Country [86] 0 0
Germany
State/province [86] 0 0
Dresden
Country [87] 0 0
Germany
State/province [87] 0 0
Essen
Country [88] 0 0
Germany
State/province [88] 0 0
Gießen
Country [89] 0 0
Germany
State/province [89] 0 0
Halle (Saale)
Country [90] 0 0
Germany
State/province [90] 0 0
Hannover
Country [91] 0 0
Germany
State/province [91] 0 0
Münster
Country [92] 0 0
Germany
State/province [92] 0 0
Rostock
Country [93] 0 0
Germany
State/province [93] 0 0
Ulm
Country [94] 0 0
Greece
State/province [94] 0 0
Athens
Country [95] 0 0
Greece
State/province [95] 0 0
Larissa
Country [96] 0 0
Greece
State/province [96] 0 0
Thessaloniki
Country [97] 0 0
Hungary
State/province [97] 0 0
Budapest
Country [98] 0 0
Hungary
State/province [98] 0 0
Pécs
Country [99] 0 0
Hungary
State/province [99] 0 0
Szeged
Country [100] 0 0
Hungary
State/province [100] 0 0
Tatabánya
Country [101] 0 0
India
State/province [101] 0 0
Gurgaon
Country [102] 0 0
India
State/province [102] 0 0
India
Country [103] 0 0
India
State/province [103] 0 0
Mangaluru
Country [104] 0 0
India
State/province [104] 0 0
New Delhi
Country [105] 0 0
Israel
State/province [105] 0 0
Ashkelon
Country [106] 0 0
Israel
State/province [106] 0 0
Haifa
Country [107] 0 0
Israel
State/province [107] 0 0
Jerusalem
Country [108] 0 0
Israel
State/province [108] 0 0
Tel HaShomer
Country [109] 0 0
Israel
State/province [109] 0 0
Zefat
Country [110] 0 0
Italy
State/province [110] 0 0
Bergamo
Country [111] 0 0
Italy
State/province [111] 0 0
Cagliari
Country [112] 0 0
Italy
State/province [112] 0 0
Firenze
Country [113] 0 0
Italy
State/province [113] 0 0
Genova
Country [114] 0 0
Italy
State/province [114] 0 0
L'Aquila
Country [115] 0 0
Italy
State/province [115] 0 0
Milano
Country [116] 0 0
Italy
State/province [116] 0 0
Pavia
Country [117] 0 0
Italy
State/province [117] 0 0
Roma
Country [118] 0 0
Japan
State/province [118] 0 0
Chiba
Country [119] 0 0
Japan
State/province [119] 0 0
Iwate
Country [120] 0 0
Japan
State/province [120] 0 0
Kyoto
Country [121] 0 0
Japan
State/province [121] 0 0
Miyagi
Country [122] 0 0
Japan
State/province [122] 0 0
Niigata
Country [123] 0 0
Japan
State/province [123] 0 0
Osaka
Country [124] 0 0
Japan
State/province [124] 0 0
Saitama
Country [125] 0 0
Japan
State/province [125] 0 0
Tokyo
Country [126] 0 0
Japan
State/province [126] 0 0
Yamaguchi
Country [127] 0 0
Japan
State/province [127] 0 0
Sagamihara-shi
Country [128] 0 0
Lithuania
State/province [128] 0 0
Kaunas
Country [129] 0 0
Lithuania
State/province [129] 0 0
Klaipeda
Country [130] 0 0
Lithuania
State/province [130] 0 0
Vilnius
Country [131] 0 0
Netherlands
State/province [131] 0 0
Amsterdam
Country [132] 0 0
Netherlands
State/province [132] 0 0
Breda
Country [133] 0 0
Netherlands
State/province [133] 0 0
Groningen
Country [134] 0 0
Netherlands
State/province [134] 0 0
Sittard-Geleen
Country [135] 0 0
Norway
State/province [135] 0 0
Bergen
Country [136] 0 0
Norway
State/province [136] 0 0
Namsos
Country [137] 0 0
Norway
State/province [137] 0 0
Oslo
Country [138] 0 0
Poland
State/province [138] 0 0
Kujawsko-pomorskie
Country [139] 0 0
Poland
State/province [139] 0 0
Mazowieckie
Country [140] 0 0
Poland
State/province [140] 0 0
Slaskie
Country [141] 0 0
Poland
State/province [141] 0 0
Wielkopolskie
Country [142] 0 0
Poland
State/province [142] 0 0
Lodz
Country [143] 0 0
Poland
State/province [143] 0 0
Lublin
Country [144] 0 0
Poland
State/province [144] 0 0
Zabrze
Country [145] 0 0
Portugal
State/province [145] 0 0
Braga
Country [146] 0 0
Portugal
State/province [146] 0 0
Lisboa
Country [147] 0 0
Portugal
State/province [147] 0 0
Matosinhos
Country [148] 0 0
Portugal
State/province [148] 0 0
Porto
Country [149] 0 0
Romania
State/province [149] 0 0
Bucuresti
Country [150] 0 0
Romania
State/province [150] 0 0
Campulung
Country [151] 0 0
Romania
State/province [151] 0 0
Cluj-Napoca
Country [152] 0 0
Romania
State/province [152] 0 0
Constanta
Country [153] 0 0
Romania
State/province [153] 0 0
Oradea
Country [154] 0 0
Romania
State/province [154] 0 0
Sibiu
Country [155] 0 0
Romania
State/province [155] 0 0
Targu Mures
Country [156] 0 0
Romania
State/province [156] 0 0
Timisoara
Country [157] 0 0
Russian Federation
State/province [157] 0 0
Barnaul
Country [158] 0 0
Russian Federation
State/province [158] 0 0
Ekaterinburg
Country [159] 0 0
Russian Federation
State/province [159] 0 0
Kaliningrad
Country [160] 0 0
Russian Federation
State/province [160] 0 0
Kazan
Country [161] 0 0
Russian Federation
State/province [161] 0 0
Kemerovo
Country [162] 0 0
Russian Federation
State/province [162] 0 0
Kirov
Country [163] 0 0
Russian Federation
State/province [163] 0 0
Krasnoyarsk
Country [164] 0 0
Russian Federation
State/province [164] 0 0
Moscow
Country [165] 0 0
Russian Federation
State/province [165] 0 0
Nizhny Novgorod
Country [166] 0 0
Russian Federation
State/province [166] 0 0
Novosibirsk
Country [167] 0 0
Russian Federation
State/province [167] 0 0
Perm
Country [168] 0 0
Russian Federation
State/province [168] 0 0
Pyatigorsk
Country [169] 0 0
Russian Federation
State/province [169] 0 0
Rostov-on-Don
Country [170] 0 0
Russian Federation
State/province [170] 0 0
Saint-Petersburg
Country [171] 0 0
Russian Federation
State/province [171] 0 0
Samara
Country [172] 0 0
Russian Federation
State/province [172] 0 0
Saransk
Country [173] 0 0
Russian Federation
State/province [173] 0 0
Smolensk
Country [174] 0 0
Russian Federation
State/province [174] 0 0
St-Petersburg
Country [175] 0 0
Russian Federation
State/province [175] 0 0
Tyumen
Country [176] 0 0
Russian Federation
State/province [176] 0 0
Ufa
Country [177] 0 0
Spain
State/province [177] 0 0
Andalucia
Country [178] 0 0
Spain
State/province [178] 0 0
Barcelona [Barcelona]
Country [179] 0 0
Spain
State/province [179] 0 0
Girona [Gerona]
Country [180] 0 0
Spain
State/province [180] 0 0
Las Palmas
Country [181] 0 0
Spain
State/province [181] 0 0
Madrid
Country [182] 0 0
Spain
State/province [182] 0 0
Pais Vasco
Country [183] 0 0
Spain
State/province [183] 0 0
Córdoba
Country [184] 0 0
Spain
State/province [184] 0 0
Lleida
Country [185] 0 0
Spain
State/province [185] 0 0
Murcia
Country [186] 0 0
Spain
State/province [186] 0 0
Málaga
Country [187] 0 0
Spain
State/province [187] 0 0
Valencia
Country [188] 0 0
Turkey
State/province [188] 0 0
Eskisehir
Country [189] 0 0
Turkey
State/province [189] 0 0
Hatay
Country [190] 0 0
Turkey
State/province [190] 0 0
Istanbul
Country [191] 0 0
Turkey
State/province [191] 0 0
Izmir
Country [192] 0 0
Turkey
State/province [192] 0 0
Izmit
Country [193] 0 0
Turkey
State/province [193] 0 0
Kütahya
Country [194] 0 0
Turkey
State/province [194] 0 0
Mersin
Country [195] 0 0
Turkey
State/province [195] 0 0
Trabzon
Country [196] 0 0
Ukraine
State/province [196] 0 0
Chernivtsi
Country [197] 0 0
Ukraine
State/province [197] 0 0
Dnipro
Country [198] 0 0
Ukraine
State/province [198] 0 0
Ivano-Frankivsk
Country [199] 0 0
Ukraine
State/province [199] 0 0
Kharkiv
Country [200] 0 0
Ukraine
State/province [200] 0 0
Kyiv
Country [201] 0 0
Ukraine
State/province [201] 0 0
Lutsk
Country [202] 0 0
Ukraine
State/province [202] 0 0
Lviv
Country [203] 0 0
Ukraine
State/province [203] 0 0
Odesa
Country [204] 0 0
Ukraine
State/province [204] 0 0
Vinnytsia
Country [205] 0 0
Ukraine
State/province [205] 0 0
Zhytomyr
Country [206] 0 0
United Kingdom
State/province [206] 0 0
Devon
Country [207] 0 0
United Kingdom
State/province [207] 0 0
Neath Port Talbot
Country [208] 0 0
United Kingdom
State/province [208] 0 0
Nottinghamshire
Country [209] 0 0
United Kingdom
State/province [209] 0 0
Oxfordshire
Country [210] 0 0
United Kingdom
State/province [210] 0 0
Bristol
Country [211] 0 0
United Kingdom
State/province [211] 0 0
Cardiff
Country [212] 0 0
United Kingdom
State/province [212] 0 0
London
Country [213] 0 0
United Kingdom
State/province [213] 0 0
Newcastle Upon Tyne
Country [214] 0 0
United Kingdom
State/province [214] 0 0
Salford

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Sanofi
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Primary Objective:

To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in NRSPMS

Secondary Objective:

To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 and relevant metabolites in NRSPMS and its relationship to efficacy and safety To evaluate pharmacodynamics (PD) of SAR442168
Trial website
https://clinicaltrials.gov/study/NCT04411641
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Sciences & Operations
Address 0 0
Sanofi
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04411641